MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (PACB) (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into ...
GAAP net income of $3.6 million for Q4 2024, marking a significant recovery from a net loss of $82.0 million in Q4 2023. Gain of $154.4 million from a successful debt restructuring, reducing the ...
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback